Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite antidepressant therapy of appropriate trial duration and dose optimization, 50-60% of depressed patients have an adequate treatment response, whereas only 35-40% achieve remission. Psychostimulants have been suggested as potential candidates to promote acceleration of response and to alleviate residual symptoms of depression. AIMS: In this review results from randomized clinical trials (RCTs) exploring the efficacy of psychostimulants in the treatment of major depressive disorder (MDD) were analyzed to clarify the current empirically founded evidence for clinical approaches involving psychostimulants. METHOD: Literature research via PubMed retrieved 846 articles. 18 RCTs reporting on the use of psychostimulants in the treatment of adult patient populations, suffering from moderate-severe depression and having no other concomitant medical illnesses, were included in this review. 14 articles provided results for unipolar depression, two for bipolar depression, whereas two articles presented mixed samples of unipolar and bipolar patients. RESULTS: Five different psychostimulants were evaluated: modafinil, methylphenidate, dexamphetamine, methylamphetamine and pemoline. Two studies examining modafinil demonstrated significant ameliorating characteristics pertaining to symptoms of depression. No clear evidence for the effectiveness of traditional psychostimulants in the therapeutic management of MDD was found. In general the quality of included trials was poor since the majority was of short-term duration, comprising relatively small sample sizes and some, especially older studies, were methodologically flawed. CONCLUSION: Clearly larger well designed placebo-controlled studies with longer follow-up accompanied by evaluations of tolerance/dependence are warranted before psychostimulants can be recommended in routine clinical practice for the treatment of MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Berridge, C. W., & Devilbiss, D. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.023 · Cited by 160
Psychostimulants for depression
Candy, B., Jones, L., Williams, R., Tookman, A., & King, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006722.pub2 · Cited by 156
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104910.75206.b9 · Cited by 144
Patkar, A. A., Masand, P. S., Pae, C.-U., Peindl, K., Hooper-Wood, C., Mannelli, P., & Ciccone, P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246212.03530.fd · Cited by 140
Markowitz, J. S., & Patrick, K. S. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140100-00004 · Cited by 123
Ravindran, A. V., Kennedy, S. H., O'Donovan, M. C., Fallu, A., Camacho, F., & Binder, C. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0112 · Cited by 119
Early augmentation of sertraline with methylphenidate
Postolache, T. T., Rosenthal, R. N., Hellerstein, D. J., Aromin, R., Kelton, G. M., Muran, J. C., & Londono, J. H. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0210c · Cited by 26
Cited by
Philipsen, A., Jans, T., Graf, E., Matthies, S., Borel, P., Colla, M., Gentschow, L., Langner, D., Jacob, C., Groß-Lesch, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2146 · Cited by 175
Witkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233627 · Cited by 105
“We acknowledge that the manner in which dopaminergic neurotransmission impinges on antidepressant effects is still not fully understood (c.f., Abbasowa et al., 2013; Bhagwagar et al., 2015).”
Stimulants for depression: On the up and up?
Malhi, G. S., Byrow, Y., Bassett, D., Boyce, P., Hopwood, M., Lyndon, W., Mulder, R., Porter, R., Singh, A., & Murray, G. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416634208 · Cited by 46
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“Overall, most studies available to date on psychostimulant efficacy as add-on treatment to antidepressants have comprised relatively small sample sizes and had short-term duration, which limit the interpretation of the results [84].”
BackgroundDopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis
Szmulewicz, A. G., Angriman, F., Samamé, C., Ferraris, A., Vigo, D., & Strejilevich, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12712 · Cited by 37
Metadata
- Authors
- Abbasowa, L., Kessing, L. V., & Vinberg, M.
- Venue
- Nordic Journal of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2013-01-07
- Volume
- 67
- Issue
- 6
- Pages
- 369-382
- ISSN
- 0029-1455 (ISSN-L)
- 0803-9488
- 1502-4725
- OpenAlex
- W2029446070
- Cited by
- 26
- References
- 10
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.